The elucidation of the pathogenesis and a search of the molecular targeted treatment of endometriosis.

子宫内膜异位症的一个方面是其慢性炎症性增殖性疾病的性质，我们认为免疫机制与发展和扩展有关。从这个假设出发，我们进行了几项研究，以找到治疗靶点。利用大鼠子宫内膜异位症模型，我们确定了两种与子宫内膜异位症发病机制相关的因子：骨桥蛋白（OPN）和L-选择素。在临床研究中，我们通过一项前瞻性、双盲、随机、安慰剂对照研究证明了具有抗炎作用的白三烯受体拮抗剂治疗子宫内膜异位症和痛经的可能性。

One aspect of endometriosis is its chronic inflammatory proliferative disease nature and we believe an immunologic mechanism is associated with the development and extension. From this hypothesis, we carried out several studies to find a treatment target. Using rat endometriosis model, we identified two factors (osteopontin (OPN) and L-selectin) associated with pathogenesis of endometriosis. In clinical studies, we proved the possibility that a leukotriene receptor antagonist which has anti-inflammatory effects was effective in treatment of endometriosis and dysmenorrhea by a prospective, double-blind, randomized, placebo-controlled study.